The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Vaxart, a South San Francisco biotech company, had to lay off staff after Robert F. Kennedy Jr. ordered a halt to the company ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

A data analysis published in a scientific journal indicates that differences with placebo are marginal for most treatments ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

Only around one in 10 common non-surgical and non-invasive treatments for lower back pain are effective, suggests a pooled ...

Kennedy Jr., the new head of the Department of Health and Human Services, has suggested that vitamin A supplements are just ...

Nobody complains that we have more cancer medicines available today than in the 1980s. Why should we complain about having ...

Low back pain is a growing problem across the world and is the leading cause of disability world wide but a recent study ...